Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages 964-971

  Gamis, Alan S ^a   Alonzo, Todd A ^b   Perentesis, John P ^c   Meshinchi, Soheil ^d  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acute myeloid leukemia; Children's oncology group

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; BORTEZOMIB; IMATINIB; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DOWN SYNDROME; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; RESEARCH;

EID: 84876424234     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24432     Document Type: Review

References (93)

1. Creutzig U, van den Heuvel-Eibrink M, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood 2012; 120: 3187-3205.
2. Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children adults in the United States, 2001-2007. Blood 2012; 119: 34-43.
3. Cooper TM, Franklin J, Gerbing R, et al. AAML03P1, a pilot study of the safety of Gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia. Cancer 2012; 118: 761-769.
4. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108: 3654-3661.
5. Ho PA, Alonzo TA, Kopecky KJ, et al. Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010; 24: 909-913.
6. Ho PA, Kutny MA, Alonzo TA, et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 57: 204-209.
7. Radhi M, Meshinchi S, Gamis A. Prognostic factors in pediatric acute myeloid leukemia. Curr Hematol Malign Rep 2010; 5: 200-206.
8. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: A report from Children's Oncology Group. Blood 2012; 120: 1581-1588.
9. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 2008; 111: 1044-1053.
10. Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol 2011; 155: 366-376.
11. Creutzig U, Zimmerman M, Dworzak M, et al. Study AML-BFM 2004: Improved survival in childhood acute myeloid leukemia without increased toxicity. Blood 2010; 116: 181.
12. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-552.
13. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011; 29: 310-315.
14. Petersdorf S, Kopecky K, Stuart R, et al. Preliminary results of Southwest Oncology Group study S0106: An international intergroup phase 3 randomized trial comparing the addition of Gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation Gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009; 114: 790.
15. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-1259.
16. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of Gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369-377.
17. Gibson B. Personal communication. 2012.
18. Canner JA, Alonzo TA, Franklin J, et al. Treatment outcomes in older adolescent and young adult (AYA) patients with newly diagnosed AML. J Clin Oncol 2011; 29 (suppl; abstr 9506).
19. Alonzo TA. COG statistician.
20. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. Br Med J 2009; 339: b4606.
21. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2328-2338.
22. Van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30: 1429-1437.
23. Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD_acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012; 119: 5133-5143.
24. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010; 115: 2372-2379.
25. Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005; 19: 1536-1542.
26. Meshinchi S, Ries RE, Farrar J, et al. Demonstration of significant clonal evolution from diagnosis to relapse in childhood AML determined by exome capture sequencing-An NCI/COG TARGET AML Study. Cancer Res 2012; 72: LB-93.
27. Feusner JH, Gregory J, Moser BK, et al. Dose-intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Study C9710. J Clin Oncol 2010; 28: 15s.
28. Sorrell AD, Alonzo TA, Hilden JM, et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group Trial A2971. Cancer 2012; 118: 4806-4814.
29. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: A report from the Children's Oncology Group Study A2971. Blood 2011; 118: 6752-6759.
30. Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 57: 56-62.
31. Ho PA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. Blood 2009; 113: 6558-6566.
32. Brown P, McIntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007; 110: 979-985.
33. Becton D, Dahl GV, Ravindranath Y, et al. Randomized use of cyclosporinA(CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 2006; 107: 1315-1324.
34. Gamis AS, Alonzo TA, Gerbing RB, et al. Remission rates in childhood acute myeloid leukemia (AML) utilizing a dose-intensive induction regimen with or without Gemtuzumab ozogamicin (GO): Initial results from the Children's Oncology Group Phase III Trial, AAML0531. Blood 2010; 116: 182.
35. Meshinchi S, Alonzo TA, Gerbing RB, et al. Identification of post-induction minimal residual disease by multidimensional flow cytometry identifies patients with AML at high risk of relapse and poor outcome-a report from the Children's Oncology Group. Blood 2010; 116: 1702.
36. Prebet T, Etienne A, Devillier R, et al. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with Gemtuzumab and cytarabine versus cytarabine. Cancer 2011; 117: 974-981.
37. Castaigne S, Pautus C, Terre C, et al. Effect of Gemtuzumab ozogamicin on survival of adult patients with denovo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet 2012; 379: 1508-1516.
38. Burnett AK, Russell NH, Hills RK, et al. Addition of Gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30: 3924-3931.
39. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. J Clin Oncol 2010; 28: 2674-2681.
40. Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003; 101: 3398-3406.
41. van der Velden VHJ, van der Sluijis-Geling A, Gibson BES, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24: 1599-1606.
42. Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM Study Group. J Clin Oncol 2006; 24: 3686-3692.
43. Alonzo TA, Ho PA, Gerbing RB, et al. Conventional cytogenetics, molecular profiling, and flow cytometric response data allow the creation of a two-tiered risk-group system for risk-based therapy allocation in childhood AML-A report from the Children's Oncology Group. Blood 2010; 116: 761.
44. Pollard JA, Alonzo T, Gerbing R, et al. Correlation of CD 33 expression level with disease characteristics and response to Gemtuzumab ozogamycin-containing chemotherapy in childhood AML. Blood 2008; 112: 148.
45. Walter RB, Alonzo TA, Gerbing RB, et al. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol 2010; 28: 2831-2838.
46. Lacayo NJ, Alonzo TA, Gayko U, et al. Sincle cell network profiling (SCNP)-based classifier to predict response to induction therapy in pediatric patients with de novo acute myeloid leukemia (AML): Validation study results. Blood 2011; 118: 3544.
47. Kutny MA, Alonzo TA, Gerbing RB, et al. TET2 SNP rs2454206 (I1762V) correlates with improved survival in pediatric acute myelogenous leukemia, a report from the Children's Oncology Group. Blood 2010; 116: 949.
48. Meshinchi S. FLT3 is a stratification factor for targeted therapy treatments in adult and pediatric AML-Phase III trials. Eur J Cancer 2011; 47: SP 126.
49. Kutny MA, Alonzo TA, Gerbing RB, et al. RUNX1 mutations in pediatric AML: A report from the Children's Oncology Group. Blood 2009; 114: 2614.
50. Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. Blood 2010; 116: 702-710.
51. Pulikkan JA, Peramangalam PS, Dengler V, et al. C/EBP alpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 2010; 116: 5638-5649.
52. Ho PA, Kuhn J, Gerbing RB, et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: A report from the children's oncology group. J Clin Oncol 2011; 29: 704-711.
53. Berman JN, Gerbing RB, Alonzo TA, et al. Prevalence and clinical implications of NRAS mutations in childhood AML: A report from the Children's Oncology Group. Leukemia 2011; 25: 1039-1042.
54. Ho PA, Kopecky KJ, Alonzo TA, et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: A report from the Children's Oncology Group and SWOG. Blood 2011; 118: 4561-4566.
55. Wen Q, Goldenson B, Silver S, et al. Integrative screening approach to identify regulators of polyploidization and targets for acute megakaryocytic leukemia. Cell 2012; 150: 1-15.
56. Lacayo NJ, Cohen A, Westfall M, et al. Single cell network profiling (SCNP) signatures predict response to induction therapy and relapse risk in pediatric patients with acute myeloid leukemia: Children's Oncology Group (COG) Study POG-9421. Blood 2010; 116: 954.
57. Redell MS, Ruiz MJ, Gerbing RB, et al. FACS analysis of Stat3/5 signaling reveals ligand sensitivity as a significant prognostic factor in pediatric AML: A Children's Oncology Group Report. Blood 2011; 118: 938.
58. Taga T, Shimomura Y, Horikoshi Y, et al. Continuous and high-dose cytarabine combined chemotherapy in children with Down syndrome and acute myeloid leukemia: Report from the Japanese Children's Cancer and Leukemia Study Group (JCCLSG) AML 9805 Down Study. Pediatr Blood Cancer 2011; 57: 36-40.
59. Tandonnet J, Clavel J, Baruchel A, et al. Myeloid leukaemia in children with Down syndrome: Report of the registry-based French experience between 1990 and 2003. Pediatr Blood Cancer 2010; 54: 927-933.
60. Abildggaard L, Ellebaek E, Gustafsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006; 85: 275-280.
61. Kudo K, Kojima S, Tabuchi K, et al. Prospective Study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: The Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007; 25: 5442-5447.
62. Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355-1360.
63. Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: Population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2005; 132: 576-583.
64. Sorrell A, Alonzo TA, Gerbing RB, et al. Remission marrow blast percentage predicts relapse risk in children with myeloid leukemia associated with Down syndrome. Pediatr Blood Cancer 2012; 58: 1039.
65. Loew T, Gamis A, Smith F, et al. Down syndrome patients with relapsed acute myelogenous leukemia. Blood 2004; 104: 215b.
66. Taga T, Saito AM, Kudo K, et al. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 2012; 120: 1810-1815.
67. Kutny MA, Moser BK, Laumann K, et al. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59: 662-667.
68. Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447-453.
69. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-{kappa}B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
70. Stapnes C, Doskeland AP, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007; 136: 814-828.
71. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 1856-1862.
72. Johnston DL, Meshinchi S, Opheim KE, et al. Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia. Br J Haematol 2003; 123: 431-435.
73. Pollard JA, Alonzo TA, Gerbing RB, et al. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood 2006; 108: 2764-2769.
74. Loken MR, Alonzo TA, Pardo L, et al. Multidimensional flow cytometry significantly improves upon the morphologic assessment of post-induction marrow remission status-Comparison of morphology and multidimensional flow cytometry: A report from the Children's Oncology Group AML Protocol AAML0531. Blood 2011; 118: 939.
75. Caligiuri MA, Strout MP, Gilliland DG. Molecular biology of acute myeloid leukemia. Semin Oncol 1997; 24: 32-44.
76. Dash A, Gilliland DG. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 49-64.
77. Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8288.
78. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3: 179-198.
79. Walter RB, Applebaum FR, Estey EH, et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012; 119: 6198-6208.
80. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260-263.
81. Moore AS, Faisal A, de Castro DG, et al. Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns. Leukemia 2012; 26: 1462-1470.
82. Grimwade D, Lo-Coco F. Acute promyelocytic leukemia: A model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959-1973.
83. Jurcic JG, Nimer SD, DeBlasio T, et al. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98: 2651-2656.
84. Lo-Coco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 503-520.
85. Miller WH Jr, Levine K, DeBlasio A, et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993; 82: 1689-1694.
86. Liu Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by RT-qPCR in core-binding factor AML allows risk-stratification and predicts relapse: Results of the UK MRC AML-15 trial. Blood 2012; 120: 2826-2835.
87. Buonamici S, Ottaviani E, Testoni N, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443-449.
88. Hughes MD, Zeng R, Miller KL, et al. Augmentation of sensitivity of FLT3/ITD assay allows detection of minimal residual disease in stem cell transplant recipients-correlation with flow cytometric MRD assessment. Blood 2010; 116: 1717.
89. Radich JP. The use of PCR technology for detecting minimal residual disease in patients with leukemia. Rev Immunogenet 1999; 1: 265-278.
90. Tobal K, Newton J, Macheta M, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000; 95: 815-819.
91. Wu D, Sherwood A, Fromm JR, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Translat Med 2012; 4: 134ra163.
92. Metzelder S, Shroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia (AML) synergizes with allo-immune effects to induce sustained responses. Leukemia 2012; 26: 2353-2359.
93. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.